Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 7Carcinoma, Renal Cell 4Squamous Cell Carcinoma of Head and Neck 3Neoplasm Metastasis 3Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Sarcoma 2Recurrence 2Lymphoma, Non-Hodgkin 2Head and Neck Neoplasms 2Colorectal Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Non-Small-Cell Lung 2Unspecified Adult Solid Tumor, Protocol Specific 1Stomach Neoplasms 1Skin Neoplasms 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Neuroblastoma 1Neoplasms 1Metastatic Castration-resistant Prostate Cancer 1Medulloblastoma 1Lymphoma 1Leukemia, B-Cell 1Leukemia 1Kidney Neoplasms 1Glioma 1Ependymoma 1Carcinoma, Merkel Cell 1Advanced Cancer 1

Interventions

Nivolumab 20Ipilimumab 10Surveys and Questionnaires 7Paclitaxel 7linrodostat 6Standard of Care 6Sirolimus 5Gemcitabine 5Bevacizumab 5temsirolimus 4relatlimab 4Pemetrexed 4Interviews as Topic 4Docetaxel 4Carboplatin 4ARRY-334543 4Vorinostat 3Erlotinib Hydrochloride 3Dasatinib 3Cetuximab 3regorafenib 2olaparib 2apatinib 2anlotinib 2abemaciclib 2Trastuzumab 2Sunitinib 2Sorafenib 2Olanzapine 2N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Cancer × bempegaldesleukin × Clear all
NCT03745807 2021-10-04

An Investigational Study of NKTR-214 Combined With Nivolumab in Japanese Participants With Advanced Solid Tumors

Bristol-Myers Squibb

Phase 1 Completed
3 enrolled

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡